Answers are grounded in this paper and cite their sources.
Background: Pembrolizumab, an anti−PD-1 antibody, is approved as adjuvant therapy for stage IIB-C and stage III melanoma by AJCC 8th ed, following complete resection. Adjuvant pembrolizumab has improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with high-risk melanoma, but many patients experience disease recurrence. V940 is an individualized neoantigen therapy that showed improved RFS and DMFS when used in combination with pembrolizumab compared with pembrolizumab alone in patients with stage III/IV melanoma in the randomized phase 2b KEYNOTE-942 study.
No takes yet. Share an insight, caveat, or question.
Weber et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: